Clinical Pearls and Future Directions for ADCs in mTNBC

In the program's closing segment, the panel shares practical pearls and reflections for clinicians. Panelists emphasize thinking of ADCs as effective, innovative chemotherapy that shifts rather than eliminates toxicity, with each agent requiring its own tailored prophylaxis to keep patients on treatment and benefiting over time. The discussion revisits sequencing, the continued role of established chemotherapy, and emerging activity in patients with brain metastases, where a multidisciplinary approach may sometimes allow systemic therapy with careful follow-up. Panelists also look ahead to the movement of ADCs into earlier, curative-intent settings through ongoing neoadjuvant and adjuvant trials, and across additional breast cancer subtypes. The faculty close with shared optimism, underscoring the importance of individualized, multidisciplinary, patient-centered care, the need for continued research and better drugs, and gratitude to the patients whose trial participation has advanced the field. Viewers leave with actionable takeaways and a hopeful perspective on the road ahead.